Vega Therapeutics Acquired by Incyte | Healthcare M&A Deal

Incyte has acquired Vega Therapeutics, a pharmaceuticals business in the hematology space, for $1.25 billion. Vega Therapeutics develops late-stage therapies for von Willebrand disease, an inherited bleeding disorder, with VGA039 designed to reduce dosing burden versus current infusion-based treatment. Incyte acquisitions in healthcare M&A focus on expanding its blood disorder pipeline as patent expiration pressure approaches for Jakafi, its top product. The strategic acquisition is expected to strengthen Incyte’s presence in hematology and diversify revenue beyond oncology, aligning with Incyte’s core R&D and commercial operating model.